(Q39835731)

15 September 2017

1 reference

title

Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life (English)

1 reference

15 September 2017

1 reference

Beam TR Jr

1

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 September 1985

1 reference

15 September 2017

1 reference

15 September 2017

volume

5

1 reference

15 September 2017

issue

5

1 reference

15 September 2017

page(s)

237-253

1 reference

Metabolism of [14C]Cefmenoxime in normal subjects after intramuscular administration

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro activity and beta-lactamase stability of cefmenoxime

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro activity of Ro 13-9904, cefuroxime, cefoxitin, and ampicillin against Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro evaluation of Ro 13-9904

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In-vitro activity of Sch 29482, MK 0787, ceftriaxone and seven other antimicrobials against 840 separate clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone: In vitro activity against 410 bacterial isolates compared with cefotaxime

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Unusual Mode of Inhibition of Citrobacter freundii β-Lactamases by Ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Susceptibility of blood isolates to various antibiotics, in particular to cephalosporins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone - a new broad-spectrum semisynthetic cephalosporin. In vitro activity against gram-negative bacilli sensitive and resistant to gentamicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

BL-S786 (Ceforanide), a New Parenteral Cephalosporin: In Vitro Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

SK&F 75073, New Parenteral Broad-Spectrum Cephalosporin with High and Prolonged Serum Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Comparative activities of 13 beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Characterization of beta-lactamase induction in Enterobacter cloacae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Effect of inoculum size on Haemophilus influenzae type b susceptibility to new and conventional antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Activity of a new cephalosporin antibiotic, Ro 13-9904 against dense populations of selected enterobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Comparison of Susceptibilities of Anaerobic Bacteria to Cefmenoxime, Ceftriaxone, and Other Antimicrobial Compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Activities of New Beta-Lactam Antibiotics Against Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

In vitro and in vivo synergy between ceftriaxone and aminoglycosides againstPseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Effect of ceftriaxone on Pseudomonas aeruginosa and Staphylococcus aureus in broth, serum, and in combination with human polymorphonuclear leukocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone: A summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-μg disks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Renal excretion of cephapirin and cephaloridine: Evidence for saturable tubular reabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics of ceftriaxone in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone pharmacokinetics in newborn infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics of Ceftriaxone in Pediatric Patients With Meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Clinical Pharmacology of Ceftriaxone in Patients with Neoplastic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone levels in blood and tissue during cardiopulmonary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Hypoprothrombobinaemic bleeding associated with ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Efficacy and safety of ceftriaxone in serious pediatric infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics and Bacteriologic Efficacy of Moxalactam, Cefotaxime, Cefoperazone, and Rocephin in Experimental Bacterial Meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Comparison of ceftriaxone and traditional therapy of bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Efficacy of ceftriaxone in serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone: in vitro studies and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone (Ro 13-9904) therapy of serious infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone therapy of serious bacterial infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone therapy of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Comparative study of ceftriaxone and aqueous procaine penicillin G in the treatment of uncomplicated gonorrhea in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Comparative Non-Blind Trial of Ceftriaxone and Gentamicin in the Treatment of Complicated Urinary Tract Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Third-Generation Cephalosporins for Polymicrobial Surgical Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Intravenous antibiotic therapy in an outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftazidime therapy of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Osteomyelitis: A Review of Clinical Features, Therapeutic Considerations and Unusual Aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Osteomyelitis: the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Systemic prophylactic antibiotics: need the 'cost' be so high?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

The place of cephalosporins in antibacterial treatment of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Ceftriaxone A Review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

Antibiotic prophylaxis in surgical procedures. A critical analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03423.X

10.1002/J.1875-9114.1985.TB03423.X

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference